VITZROCELLLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

VITZROCELLLtd heeft een totaal eigen vermogen van ₩263.2B en een totale schuld van ₩502.8M, wat de schuld-eigenvermogensverhouding op 0.2% brengt. De totale activa en totale passiva bedragen respectievelijk ₩292.6B en ₩29.4B. De EBIT VITZROCELLLtd is ₩43.3B waardoor de rentedekking -15.6 is. Het heeft contanten en kortetermijnbeleggingen van ₩117.1B.

Belangrijke informatie

0.2%

Verhouding schuld/eigen vermogen

₩502.78m

Schuld

Rente dekkingsratio	-15.6x
Contant	₩117.05b
Aandelen	₩263.21b
Totaal verplichtingen	₩29.43b
Totaal activa	₩292.64b

Recente financiële gezondheidsupdates

VITZROCELLLtd (KOSDAQ:082920) Seems To Use Debt Quite Sensibly

Apr 07

VITZROCELL (KOSDAQ:082920) Seems To Use Debt Quite Sensibly

Dec 02

Recent updates

Estimating The Intrinsic Value Of VITZROCELL Co.,Ltd. (KOSDAQ:082920)

Aug 07

VITZROCELLLtd (KOSDAQ:082920) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 27

Could The Market Be Wrong About VITZROCELL Co.,Ltd. (KOSDAQ:082920) Given Its Attractive Financial Prospects?

Feb 28

Could The VITZROCELL Co.,Ltd. (KOSDAQ:082920) Ownership Structure Tell Us Something Useful?

Feb 07

VITZROCELLLtd (KOSDAQ:082920) Shareholders Have Enjoyed An Impressive 120% Share Price Gain

Jan 17

Here's What We Like About VITZROCELL's (KOSDAQ:082920) Upcoming Dividend

Dec 24

Is VITZROCELL Co., Ltd. (KOSDAQ:082920) A Great Dividend Stock?

Dec 23

VITZROCELL (KOSDAQ:082920) Seems To Use Debt Quite Sensibly

Dec 02

VITZROCELL Co., Ltd.'s (KOSDAQ:082920) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Nov 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₩214.1B ) A082920 } overtreffen de korte termijn passiva ( ₩27.1B ).

Langlopende schulden: De kortetermijnactiva A082920 ( ₩214.1B ) overtreffen de langetermijnschulden ( ₩2.3B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: A082920 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van A082920 is de afgelopen 5 jaar gedaald van 0.7% naar 0.2%.

Schuldendekking: De schuld van A082920 wordt goed gedekt door de operationele kasstroom ( 7125.5% ).

Rentedekking: A082920 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

VITZROCELLLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

VITZROCELLLtd (KOSDAQ:082920) Seems To Use Debt Quite Sensibly

VITZROCELL (KOSDAQ:082920) Seems To Use Debt Quite Sensibly

Recent updates

Now 22% undervalued

Third quarter 2024 earnings released: EPS: ₩366 (vs ₩337 in 3Q 2023)

Investor sentiment improves as stock rises 16%

Now 20% undervalued

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: ₩567 (vs ₩806 in 2Q 2023)

Estimating The Intrinsic Value Of VITZROCELL Co.,Ltd. (KOSDAQ:082920)

Now 19% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 23% overvalued after recent price rise

Now 21% undervalued

Now 21% undervalued

VITZROCELLLtd (KOSDAQ:082920) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of ₩200 per share at 1.2% yield

Third quarter 2023 earnings released: EPS: ₩337 (vs ₩532 in 3Q 2022)

Now 21% undervalued after recent price drop

VITZROCELL Co.,Ltd. (KOSDAQ:A082920) announces an Equity Buyback for KRW 3,600 million worth of its shares.

Now 22% undervalued after recent price drop

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 15%

Consensus revenue estimates increase by 11%

Investor sentiment improves as stock rises 19%

First quarter 2023 earnings released: EPS: ₩412 (vs ₩177 in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 15%

Consensus revenue estimates increase by 10%

Upcoming dividend of ₩150 per share

Price target increased to ₩21,000

No independent directors

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 11%

No independent directors

Price target decreased to ₩17,800

Upcoming dividend of ₩120 per share

Third quarter 2021 earnings released: EPS ₩237 (vs ₩143 in 3Q 2020)

Investor sentiment improved over the past week

Price target increased to ₩20,700

First quarter 2021 earnings released: EPS ₩246 (vs ₩288 in 1Q 2020)

VITZROCELLLtd (KOSDAQ:082920) Could Be Struggling To Allocate Capital

VITZROCELLLtd (KOSDAQ:082920) Seems To Use Debt Quite Sensibly

Is VITZROCELL Co.,Ltd. (KOSDAQ:082920) A Smart Choice For Dividend Investors?

Price target lowered to ₩19,200

Could The Market Be Wrong About VITZROCELL Co.,Ltd. (KOSDAQ:082920) Given Its Attractive Financial Prospects?

New 90-day low: ₩14,950

Could The VITZROCELL Co.,Ltd. (KOSDAQ:082920) Ownership Structure Tell Us Something Useful?

VITZROCELLLtd (KOSDAQ:082920) Shareholders Have Enjoyed An Impressive 120% Share Price Gain

Here's What We Like About VITZROCELL's (KOSDAQ:082920) Upcoming Dividend

Is VITZROCELL Co., Ltd. (KOSDAQ:082920) A Great Dividend Stock?

New 90-day low: ₩16,050

VITZROCELL Co., Ltd. announced that it expects to receive KRW 20 billion in funding from NongHyup Bank, Samsung Securities Co.,Ltd., Kb-Brain Kosdaq Scale-Up New Technology Business Investment Fund

VITZROCELL (KOSDAQ:082920) Seems To Use Debt Quite Sensibly

VITZROCELL Co., Ltd.'s (KOSDAQ:082920) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

First half earnings released

New 90-day high - ₩19,350

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven